Equity research analysts covering Eledon Pharmaceuticals (ELDN) maintain a strong consensus "Buy" rating, supported by favorable coverage from major healthcare investment banking firms. Financial institutions tracking the clinical-stage biopharmaceutical company have issued bullish 12-month price targets ranging between $7.00 and $12.00, driven largely by optimism surrounding pipeline advancements in organ transplantation and immunology clinical trials.